The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Myelin oligodendrocyte glycoprotein (MOG)–IgG is a biomarker associated with central nervous system–demyelinating disorders termed MOG-IgG–associated disorders. These disorders have overlapping clinical features, including optic neuritis and myelitis, with aquaporin-4 (AQP4)–IgG–positive neuromyelitis optica spectrum disorders. These disorders are hypothesized to be biologically distinct; AQP4-IgG–positive neuromyelitis optica spectrum disorders are autoimmune astrocytopathies, whereas MOG-IgG–associated disorders are postulated to be autoimmune oligodendrocytopathies.1 Despite their immunopathogenic differences, there are rare reports of patients with dual positivity of MOG-IgG and AQP4-IgG.2,3 We aimed to determine the frequency, sex ratio, and coexistence of glial antibodies (AQP4-IgG and MOG-IgG) in adults and children undergoing evaluation for suspected central nervous system–demyelinating diseases. Via JAMA Neurology.